VIRI
Virios Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 0.2068
- Prev close
- 0.155
- Mkt cap
- 206.50K
- Vol
- 42.36M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.143
- High
- 0.2068
- Forward P/E
- -0.97
- Beta
- 1.58
- Short ratio
- 0.64
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2024
- 50-d avg
- 4.51
- 200-d avg
- 7.69
- 1y target
- 3.00
Key statistics
- Market cap
- 206.50K
- Enterprise value
- 122.01K
- Trailing P/E
- 0.00
- Forward P/E
- -0.97
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.05
- EPS (TTM)
- -5.75
- Beta
- 1.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -2.43M
- Total cash
- 3.02M
- Total debt
- 0
- Return on equity
- -119.56%
- Shares outstanding
- 1.33M
- Short % of float
- 1.76%
- 50-day average
- 4.51
- 200-day average
- 7.69
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 3.00
- Target (high)
- 5.00
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.06 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.09 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.10 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 19, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 14, 2021 | HC Wainwright & Co. | init | — | Buy |
About Virios Therapeutics, Inc.
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- virios.com
News
- Analyzing Virios Therapeutics (NASDAQ:VIRI) & Palatin Technologies (PINK:PTNT)
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
- Virios Therapeutics Announces Second Quarter 2024 Financial Results
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
- Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
- Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on VIRI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUNCAN GREGORY SCOTT | Chief Executive Officer | Purchase | Aug 16, 2023 | 57,461 |
| PRIDGEN WILLIAM L | Director | Purchase | Aug 20, 2023 | 0 |
| WHITLEY RICHARD JAMES | Director | Sale | Dec 7, 2022 | 700 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.10% | 210,996 | 291.17K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.77% | 147,269 | 203.23K | Jun 29, 2023 |
| State Street Corporation | 0.27% | 52,828 | 72.90K | Jun 29, 2023 |
| Susquehanna International Group, LLP | 0.27% | 52,639 | 72.64K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.24% | 46,400 | 64.03K | Jun 29, 2023 |
| Citadel Advisors Llc | 0.17% | 33,298 | 45.95K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.09% | 208,883 | 288.26K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.70% | 134,121 | 230.69K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.17% | 33,485 | 57.59K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.08% | 14,707 | 25.30K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 3,038 | 5.22K | May 30, 2023 |